TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC 0.01 0.1 1 10 100 0.0 0.4 0.8 1.2 1.6 SE(log OR)

Slides:



Advertisements
Similar presentations
J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.
Advertisements

Stone p2203/Abstract/ Conclusions
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
“Randomized Comparison between Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs. Paclitaxel (Taxus vs.Costar) Eluting Stents in Coronary Lesions:
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The FRONTIER Stent Registry: Safety and Feasibility.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Risk in Clopidogrel-Treated Patients.
Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent.
Volume 54, Issue 1, Pages (August 2009)
Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease  Ralf.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.
Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.
Circ Cardiovasc Interv
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
NOACs, AF, and PCI: What Do the Latest Data Suggest?
SIRIUS Trial: Diameter Restenosis
TAXUS II and IV: two-year follow-up
Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease  Ralf.
Primary endpoint at 1 year
American College of Cardiology Presented by Dr. Stephan Windecker
Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.
REALITY: 8 month results
BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.
Presented at ACC 2003 Late Breaking Clinical Trials
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Main branch restenosis at 1 year
(p = 0.32 for noninferiority)
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.
ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.
Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.
Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD 
TAXUS VI Randomized Trial of Moderate-Rate Release Polymer-Based Paclitaxel-Eluting TAXUS Stent for the Treatment of Longer Lesions Three Year Clinical.
MACE: Death, MI or TLR at 5 years
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Primary safety endpoint
(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
FIELD: Primary outcome
Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Outcomes Number of events† Total person-years† aHR‡ (95%CI)
Outcomes Number of events† Total person-years† aHR‡ (95%CI)
Presentation transcript:

TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR) OR SE(log OR) OR SE(log OR) OR SE(log OR) OR

Funnel plot (according to outcomes) for studies included in the meta-analysis SUPPLEMENTAL FIGURE 1 MI E Stent Thrombosis F SE(log OR) OR SE(log OR) OR

Odds Ratios of All Cause Mortality SUPPLEMENTAL FIGURE 2

SUPPLEMENTAL FIGURE 3 Odds Ratios of Target Lesion Revascularization

SUPPLEMENTAL FIGURE 4 Odds Ratios of Target Vessel Revascularization

SUPPLEMENTAL FIGURE 5 Odds Ratios of Major Adverse Cardiac Events